Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Non-randomized, Multi-center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients.

NCT00836875 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00836875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00836875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Non-randomized, Multi-center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2009
Completion date
May 31, 2013
Enrollment
31 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

invasive aspergillosis